The replacement of chlorofluorocarbon (CFC) propellants with hydrofluoroalkane-134a (HFA), and the introduction of a pressurized metered dose inhaler (pMDI) in the recent reformulation of beclomethasone dipropionate (BDP), has resulted in a product with aerosol particles of a smaller mean mass aerodynamic diameter (MMAD) than conventional CFC-BDP MDIs (1,2).
Ititroduction
The replacement of chlorofluorocarbon (CFC) propellants with hydrofluoroalkane-134a (HFA), and the introduction of a pressurized metered dose inhaler (pMDI) in the recent reformulation of beclomethasone dipropionate (BDP), has resulted in a product with aerosol particles of a smaller mean mass aerodynamic diameter (MMAD) than conventional CFC-BDP MDIs (1,2).
(3). While conventional CFC-BDP inhalers produce relatively large particles with a mean size of 3.5-4*0pm, the new HFA-BDP formulation delivers an extrafine aerosol of active compound with a mean particle size of l-1 pm (Fig. I ) in a warmer and more gentle spray ( Fig. 2) (4) . This would be expected to improve drug deposition throughout the large and small airways.
The purpose of the current report is to present data showing that this new formulation of HFA-BDP (QVARTM, 3M Pharmaceuticals, St Paul, MN, U.S.A.) is at least as effective in alleviating the symptoms of asthma as conventional CFC-BDP inhalers, when used at a significantly lower dose. To support this assumption, data comparing the new HFA-BDP formulation with conventional CFC-BDP formulations is presented, namely: patterns of inhaled corticosteroid (ICS) distribution in the oropharynx and lungs; efficacy/potency ratios as measured by pharmacodynamic analysis; the clinical effect of switching from a CFC-BDP to a half dose of HFA-BDP, and the efficacy of long-term use of HFA-BDP in patients with moderate asthma.
The lung distribution of HFA-BDP and CFC-BDP in the pulmonary and oropharyngeal airways has been compared using technetium 99 m labelled BDP (5) . Even after optimal use, CFC-BDP MDIs typically deliver no more than 10% of the inhaled drug to the lungs, the residual product remaining in the oropharynx where it provides little therapeutic benefit. In contrast, the new HFA-BDP formulation delivers approximately 60% of the drug to the lungs.
Efficacy/potency ratio

HFA-BDP
HFA-BDP is a completely new preparation of BDP, which has been recently formulated to meet CFC-free requirements. To accomodate the new formulation, which, unlike CFC-MDIs, is a solution rather than a suspension of drug in propellant, different parts of the inhaler, including the valve (elastomers, seals and gasket) have been modified. In addition, to optimize ICS deposition in the airways, the actuator has been redesigned.
By improving drug delivery to the airways, the new HFA-BDP formulation should also enhance respiratory function.
To test this assumption, a protocol was designed to compare CFC-BDP with HFA-BDP in over 300 patients with moderate asthma who required regular use of ICS. In this multicentre, randomized, parallel group, blinded study, following a run-in period of 7 to I4 days (during which time the patients continued to receive their usual ICS medication), the patients entered an ICS washout period during which dependence on ICS to maintain asthma control was established. Subsequently, patients were randomized to
The deposition pattern of BDP particles in the lungs is a function of several factors, including respiratory tract geometry, airflow, particle diameter and density, and the time spent in the airways during breath-holding. receive one of six possible treatments (100, 400 or 800pgday-' of CFC-BDP or 100, 400 or 800pgday-' of HFA-BDP) for a period of 6 weeks (6). Both formulations were of the SOpgpuff-' ex-valve strength, and a doubledummy, modified blind technique was used, requiring nine puffs, twice daily, from three different MDIs. Spacers were not allowed. Treatment efficacy was assessed during almost daily patient visits. In addition, the patients' MD1 technique was reviewed and corrected where necessary. The study showed a clear benefit for HFA-BDP treatment compared to CFC-BDP treatment at all doses, as measured by both the mean change from baseline in forced expiratory volume in 1 set (FEV,) and in forced expiratory flow between 25% and 75% of vital capacity change from baseline in FEF2s7S0,0 at week 6 (Fig. 4) concluded that there was a shift to the left for HFA-BDP compared to CFC-BDP. Using these data, a dosecomparison relationship indicates that it would take 2.6 and 3.2 times the dose of CFC-BDP (compared to HFA-BDP) to obtain the same improvement in FEVi and FEFzs-r5%, respectively, as predicted for HFA-BDP.
The effects of switching from a conventional CFC-BDP to an HFA-BDP at a ratio of 2.5:1
To further confirm the potency ratio between HFA-BDP and conventional CFC-BDPs a total of 149 patients were included in a double-blind, double-dummy, parallel-group, multicentre, randomized study, which compared the efficacy of HFA-BDP 400 pgday -' W. CFC-BDP lOOOpgday-' over a IO-week period in patients with moderate asthma (7). Prior to randomization, all patients received CFC-BDP IOOOpgday-' during a 4-week run-in period. No significant difference in symptom scores and pulmonary function parameters [morning peak expiratory flow (AM PEF), FEV,, and PCzaFEVi] was recorded between the two groups at the end of treatment (Fig. 5) , indicating that HFA-BDP 400 pgday-' provides an equivalent control of asthma symptoms to CFC-BDP IOOOpgday-'. This result confirms the prediction of a 2*5:1 potency ratio between the two formulations.
Long-term maintenance of asthma control
The long-term efficacy of HFA-BDP (200-800pgday-') was compared to CFC-BDP (400-1600 pg day-') in a randomized prospective study of 1Zmonths' duration (8) . treatment following the switch from CFC-BDP to half the Patients participating in the study had a 26 month history dose of HFA-BDP. In addition, there was no significant of asthma and were receiving CFC-BDP 400-difference between the time to onset of acute exacerbations 1600pgday-'. Patients were randomized to the same dose or increased asthma symptoms (Fig. 6) (9) . Finally, the of CFC-BDP (n = 119) or to approximately half the dose of long-term Juniper overall Quality of Life score (lo), was HFA-BDP (n = 354). The study clearly demonstrated that significantly higher in the HFA-BDP group after 12 months asthma control was maintained during the 12 months of of treatment (Fig. 7 ) (8). 
Conclusion
In conclusion, compared to conventional CFC-BDP formulations, the new HFA-BDP formulation improves drug deposition in the lungs while reducing oropharyngeal deposition. The resulting greater efficacy of the new formulation is proportional to the efficiency of lung delivery, which is a result of improvements in the design of the inhalation device and the use of HFA 134 as a propellant. Other advantages of the new formulation include lower dosage requirements (2-2.5:1 dose ratio) and an effective long-term maintenance of asthma control with clear patient benefits in quality of life.
